CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $167,852 | -33.6% | 3,698 | -17.9% | 0.00% | -100.0% |
| Q2 2023 | $252,967 | -60.1% | 4,506 | -71.1% | 0.00% | -66.7% |
| Q4 2022 | $633,896 | -87.6% | 15,594 | -80.9% | 0.00% | -93.0% |
| Q1 2022 | $5,122,000 | +139.9% | 81,592 | +189.6% | 0.04% | +168.8% |
| Q4 2021 | $2,135,000 | +16.4% | 28,178 | +148.8% | 0.02% | -23.8% |
| Q2 2021 | $1,834,000 | -16.5% | 11,327 | -21.0% | 0.02% | -32.3% |
| Q4 2020 | $2,196,000 | +50.4% | 14,344 | -17.8% | 0.03% | +47.6% |
| Q3 2020 | $1,460,000 | +79.6% | 17,455 | +30.8% | 0.02% | -19.2% |
| Q4 2019 | $813,000 | – | 13,348 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |